Insulin glargine

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Insulin glargine

Examples of brand names: Lantus [EU/DE]

ATC code: A10AE04

Main use (for orientation): Diabetes

Documented research summary

The full text of a single uncontrolled cat case describes lower glucose measurements and reduced insulin glargine administration after adding a CBD-rich, THC-containing extract. Veterinary observation without controlled evidence; cannot be extrapolated to humans or pure CBD. Contradictions concerning extract composition and laboratory limits explicitly documented.

Uncertainties and limitations

One animal; repeated measurements are not independent experimental animals. The 24:1 ratio in the text does not match 6.4:0.2 mg/ml in the table. Creatinine/urea exceed the tabulated reference ranges; therefore do not uncritically adopt a safety claim.

Missing data do not establish safety. Research is limited by the documented sources, search terms, languages and accessibility.

Separately recorded findings

1 separately recorded finding. Each statement applies to its documented study context.

CBD-rich cannabis extract (contains THC) – laboratory and animal studies

Finding ID: B0434

Type of result: Uncontrolled veterinary signal

Observation: In one cat, the mean of repeated home glucose measurements fell from 244.47 to 147.88 mg/dl after adding the extract; the glargine dose was reduced from 5 to 4 IU per administration.

Mechanism: Uncontrolled veterinary course with glargine plus additional cannabis extract; mechanism not demonstrated.

Study type: Veterinary single case report

Context studied: 18-year-old cat; n=1 animal, 34 glucose measurements before and 17 afterwards, no control arm. Long-acting glargine plus CBD-rich, THC-containing extract.

Clinical interpretation: Cannot be quantified for humans

Limitations and uncertainties: No human extrapolation or isolated CBD effect. Contradiction between the text's 24:1 ratio and table concentrations of 6.4:0.2 mg/ml; creatinine/urea above stated reference limits. No confirmation of safety from this report. The authors excluded stress-associated high glucose readings from analysis; additional selection uncertainty.

Original sources for this finding: Use of Cannabidiol-Dominant Extract as Co-Adjuvant Therapy for Type 2 Diabetes Mellitus Treatment in Feline: Case Report. [VD_MED_39474238]

References and access status

[VD_LABEL_D0261] LANGLARA (INSULIN GLARGINE-ALDY) INJECTION, SOLUTION [LANEXA BIOLOGICS, LLC] – DailyMed SPL

Original source / bibliographic reference

Authors: Marketing authorisation holder / label provider according to the linked DailyMed product information

Year: 2026

Source type: Regulatory product information (US SPL)

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[VD_MED_39474238] Use of Cannabidiol-Dominant Extract as Co-Adjuvant Therapy for Type 2 Diabetes Mellitus Treatment in Feline: Case Report.

Original source / bibliographic reference

Authors: Massabo JI, Puiatti G, Ferrero P.

Year: 2024

Source type: other; Journal Article

DOI: 10.1159/000541034

PMID: 39474238

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – full-text access according to the literature database – Archive attribution confirmed by Europe PMC metadata. Direct retrieval was not fully verified here; access may require a browser check.

Europe PMC – full-text access according to the literature database – Listed as freely available HTML full text in the official Europe PMC metadata. Direct retrieval was not fully verified here.

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility